Market Overview

Biogen Up Sharply On Promising Alzheimer's Results

Related BIIB
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
5 Biggest Price Target Changes For Wednesday
The Vetr community has downgraded $BIIB to 3-Stars (Vetr)

Shares of Biogen Idec Inc (NASDAQ: BIIB) were moving sharply higher Tuesday morning following news that its Alzheimer's drug showed promising results and the company said it would proceed with a late-stage trial.

The drug, BIIB037, reduces beta amyloid in the brain, a key contributor to plaque that factors into Alzheimer's disease. The announcement came at the Deutsche Bank BioFEST conference.

Meg Tirrell of CNBC tweeted several highlights:

Shares of Biogen were trading up 6.1 percent at $327.38.

Posted-In: News Health Care General


Related Articles (BIIB)

View Comments and Join the Discussion!